Each of these four genetic patterns associated with reduced susceptibility to amprenavir produces some cross resistance to ritonavir but susceptibility to indinavir, nelfinavir and saquinavir is generally retained.

Each of these four genetic patterns associated with reduced susceptibility to amprenavir produces some cross resistance to ritonavir but susceptibility to indinavir, nelfinavir and saquinavir is generally retained.

Failure of some organs, influenza like illness, increased sensitivity to heat and cold, feeling of

Sensitivity

Sensitivity

Susceptibility

sensitivity

pins and needles, unusual sensitivity to stimuli of the senses, decreased skin sensitivity, tremors,

The M184V RT mutant shows a 4 fold decrease in susceptibility to didanosine and zalcitabine the clinical significance of these findings is unknown.

ISO Speed

ISO Speed

8 Microbiological Susceptibility

Sensitivity Insensitivity

Candida isolates with reduced susceptibility to anidulafungin have not been isolated from treated patients.

Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may affect susceptibility to ciprofloxacin.

It is suspected that some of them may have been beneficial by providing protection against bacterial infections.

Uncommon side effects affect 1 to 10 users in 1,000 Slow heart rate. Make you sensitive to sunlight. Hair loss.

In the early stages of treatment, some people may feel dizzy or faint (with a slow heart rate), especially when getting up from a lying or sitting position.

Viruses selected in these conditions and showing decreased susceptibility to darunavir (range

This will usually pass on its own but if it does not, tell your doctor.

Uncommon side effects affect 1 to 10 users in 1,000 134 Slow heart rate. Make you sensitive to sunlight. Hair loss.

Uncommon side effects affect 1 to 10 users in 1,000 Slow heart rate. Make you sensitive to sunlight. Hair loss.

Grab sensitivity

Discrimination and Sensitivity

Identification of determinants of decreased susceptibility to darunavir in those viruses is under investigation.

Show camera exposure and sensitivity

Analytical balance, accurate to 0,0002 g.

Analytical balance, accurate to 0,0002 g.

Analytical balance accurate to 0,0002 g.

HIV 1 isolates with a decreased susceptibility to amprenavir have been selected during in vitro serial passage experiments.

In

M184V mutants display greatly reduced susceptibility to lamivudine and show diminished viral replicative capacity in vitro.

increased blood decreased blood pressure

While the test is useful for field virus strains which multiply easily in cell cultures of porcine origin, this is not true of the greater part of the lapinised strains, which are not revealed by the END test.

Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may affect susceptibility to ciprofloxacin.

Sensitization (disambiguation) Sensitizer (disambiguation)

N.B. Hog cholera virus and virus of 'bovine viral diarrhoea'

Preclinical studies could provide some information regarding the possible differences in sensitivity to retinotoxicity in young and adult animals.

Short attention span, slowness of thought, memorisation difficulty, rapid mental tiredness, intolerance to noise, mood swings, lasting longer than 2 years

Reduced susceptibility to amprenavir was associated with virus that had developed I50V or I84V or V32I I47V or I54M mutations.

Reduced susceptibility to amprenavir was associated with virus that had developed I50V or I84V or V32I I47Vor I54M mutations.

In infections caused by Pseudomonas aeruginosa with proven sensitivity to ceftriaxone a combination with amino glycosides is warranted to avoid secondary resistance.

Unusual, increased or altered sensitivity to sensory stimulation, tingling or numbness feeling,

Unusual, increased or altered sensitivity to sensory stimulation, sun allergy, eczema, increased

stimuli of the senses, seizures (see Section 2